Related Experiment Videos
Cost analysis of glaucoma medications
S D Vold1, D A Wiggins, J Jackimiec
1Department of Surgery, Scott & White Memorial Hospital and Clinic, Texas A&M College of Medicine, Temple 76508, USA.
Journal of Glaucoma
|April 27, 2000
Summary
Glaucoma medication costs varied significantly in 1998, with latanoprost being the most expensive per patient annually. This medication cost variability may impact long-term glaucoma patient management.
Area of Science:
- Ophthalmology
- Health Economics
- Pharmacoeconomics
Background:
- Glaucoma is a leading cause of irreversible blindness worldwide.
- Effective management relies on consistent medication adherence.
- Understanding medication costs is crucial for patient and healthcare system sustainability.
Purpose of the Study:
- To determine the annual cost of glaucoma medications for patients and the Health Plan in 1998.
- To analyze cost variations among different glaucoma drug classes and formulations.
Main Methods:
- Retrieved prescription data for glaucoma medications from a hospital pharmacy database for the year 1998.
- Calculated per-patient per-year costs and per-unit costs for all prescribed glaucoma medications.
Main Results:
- Latanoprost (Xalatan) was the most expensive medication per patient annually at $337.
- Betaxolol hydrochloride (Betoptic-S) had the highest cost per unit at $51.
- Significant cost differences were observed across various glaucoma treatments, including dorzolamide, brimonidine tartrate, and timolol formulations.
Conclusions:
- The substantial variability in glaucoma medication costs presents a challenge for long-term patient management.
- Cost-effectiveness and accessibility of treatments should be considered in glaucoma care strategies.